Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: A description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 5, 2004, Pages 287-297

  Fraser, Graeme A M ^a   Walker, Irwin I ^a,h   Russell, J ^b   Larratt, L ^c   Davis, J ^d   Hogge, D ^e   Voralia, M ^f   Rubinger, M ^g   Schroeder, M ^g   Doyle, J ⁱ   Messner, H ^j   Berinstein, N ^k   Howson Jan, K ^l   Lopez, P ^m   Huebsch, I ⁿ   Moquin, J P ^o   Roy, J ^p   Champagne, M ^q   Laneuville, P ^r   Mitchell, D ^s   Lachance, S ^t   Cantin, G ^u   Couture, F ^u   Couban, S ^v   Duggan, P ^w   more..

^a MCMASTER UNIVERSITY   (Canada)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d BC CHILDREN S HOSPITAL   (Canada)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

^f Saskatoon Cancer Center   (Canada)

^g CANCERCARE MANITOBA   (Canada)

^h HAMILTON HEALTH SCIENCES   (Canada)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^l LONDON HEALTH SCIENCES CENTRE   (Canada)

^m Sudbury NE Ontario Reg Cancer Ctr   (Canada)

ⁿ UNIVERSITY OF OTTAWA   (Canada)

^o HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^p MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^q UNIVERSITY OF MONTREAL   (Canada)

^r Royal Victoria Hospital Barrie   (Canada)

^s MONTREAL CHILDREN S HOSPITAL   (Canada)

^t MONTREAL GENERAL HOSPITAL   (Canada)

^u LAVAL UNIVERSITY   (Canada)

^v QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^w Health Sciences Centre St John's   (Canada)

more..

Author keywords

Cytomegalovirus disease; Guidelines; Hematopoietic stem cell transplantation

Indexed keywords

ACICLOVIR; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIGEN PP65; DNA; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANADA; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE CONTROL; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LUNG LAVAGE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEDICAL SOCIETY; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PATIENT CARE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROPHYLAXIS; RECIPIENT; SEROLOGY; TIME; UNITED STATES; VIRUS CULTURE;

EID: 1942424803     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2003.10.007     Document Type: Article

References (49)

1. Meyers J.D. Flournoy N. Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation J Infect Dis 153 1986 478-488
2. Meyers J.D. Reed E.C. Shepp D.H. et al. Acyclovir for prevention of cytomegalovirus and disease after allogeneic marrow transplantation N Engl J Med 318 1988 70-75
3. Wingard J.R. Chen D.Y. Burns W.H. et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation Blood 71 1988 1432-1437
4. Goodrich J.M. Bowden R.A. Fisher L. Keller C. Schoch G. Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 118 1993 173-178
5. Winston D.J. Ho W.G. Bartoni K. et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial Ann Intern Med 118 1993 179-184
6. Reed E.C. Bowden R.A. Dandliker P.S. Lilleby K.E. Meyers J.D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants Ann Intern Med 109 1988 783-788
7. Schmidt G.M. Kovacs A. Zaia J.A. et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients Transplantation 46 1988 905-907
8. Schmidt G.M. Horak D.A. Niland J.C. Duncan S.R. Forman S.J. Zaia J.A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group N Engl J Med 324 1991 1005-1011
9. Ljungman P. Engelhard D. Link H. et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group Clin Infect Dis 14 1992 831-835
10. Ljungman P. Biron P. Bosi A. et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation Bone Marrow Transplant 13 1994 209-212
11. Reusser P. Risher L.D. Buckner C.D. Thomas E.D. Meyers J.D. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment Blood 75 1990 1888-1894
12. Boeckh M. Gooley T.A. Reusser P. Buckner C.D. Bowden R.A. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation J Infect Dis 172 1995 939-943
13. Griffeths R.I. Bass E.B. Powe N.R. Anderson G.F. Goodman S. Wingard J.R. Factors influencing third party payer costs for allogeneic BMT Bone Marrow Transplant 12 1993 43-48
14. Emanuel D. Cunningham I. Jules-Elysee K. et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin Ann Intern Med 109 1988 777-782
15. Sayers M.H. Anderson K.C. Goodnough L.T. et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection Ann Intern Med 116 1992 55-62
16. Tabbara I.A. Zimmerman K. Morgan C. Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results Arch Intern Med 162 2002 1558-1566
17. Bowden R.A. Slichter S.J. Sayers M.H. Mori M. Cays M.J. Meyers J.D. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant Blood 78 1991 246-250
18. van Prooijen H.C. Visser J.J. van Oostendorp W.R. de Gast G.C. Verdonck L.F. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters Br J Haematol 87 1994 144-147
19. Goodrich J.M. Mori M. Gleaves C.A. et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation N Engl J Med 325 1991 1601-1607
20. Prentice H.G. Gluckman E. Powles R.L. et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group Lancet 343 1994 749-753
21. Salzberger B. Bowden R.A. Hackman R.C. Davis C. Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome Blood 90 1997 2502-2508
22. Avery R.K. Adal K.A. Longworth D.L. Bolwell B.J. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy Bone Marrow Transplant 26 2000 763-767
23. Humar A. Lipton J. Messner H. McGreer A. Mazzulli T. A cross-Canada survey of cytomegalovirus prevention and treatment practices in bone marrow transplant recipients Can J Infect Dis 10 1999 410-415
24. Centers for Disease Control and Prevention, Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Biol Blood Marrow Transplant 6 2000 659-727
25. Crippa F. Holmberg L. Carter R.A. et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation Biol Blood Marrow Transplant 8 2002 281-289
26. Konoplev S. Champlin R.E. Giralt S. et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients Bone Marrow Transplant 27 2001 877-881
27. Fassa A.B.T. Bolanos-Meade J. Buddharaju L.N. et al. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma Br J Haematol 112 2001 237-241
28. Grigg A. Chapman R. Szer J. Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine Bone Marrow Transplant 21 1998 619-621
29. Bowden R.A. Slichter S.J. Sayers M. et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant Blood 86 1995 3598-3603
30. Narvios A.B. Przepiorka D. Tarrand J. Chan K.W. Champlin R. Lichtiger B. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients Bone Marrow Transplant 22 1998 575-577
31. De Witte T. Schattenberg A. Van Dijk B.A. et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors Transplantation 50 1990 964-968
32. Nichols K.G. Price T.H. Gooley T. Corey L. Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products Blood 101 2003 4195-4200
33. Laupacis A. Brown J. Costello B. et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement Transfusion 41 2001 560-569
34. Reuser P. Einsele H. Lee J. et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation Blood 99 2002 1159-1164
35. Ljugman P. de la Camara R. Millpied N. et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants Blood 99 2002 3050-3056
36. Bacigalupo A. Tedone E. Isaza A. et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigenemia positive cell numbers with transplant-related mortality Bone Marrow Transplant 16 1995 155-161
37. Boeckh M. Stevens-Ayers T. Bowden R.A. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation J Infect Dis 174 1996 907-912
38. Boeckh M. Gooley T.A. Myerson D. Cunningham T. Schoch G. Bowden R.A . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 88 1996 4063-4071
39. Hebart H. Muller C. Loffler J. Jahn G. Einsele H. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation Bone Marrow Transplant 17 1996 861-868
40. Ljungman P. Lore K. Aschan J. et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients Bone Marrow Transplant 17 1996 583-587
41. Boeckh M. Gallez-Hawkins G.M. Myerson D. Zaia J.A. Bowden R.A. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture Transplantation 64 1997 108-113
42. Humar A. Lipton J. Welsh S. Moussa G. Messner H. Mazzulli T. A randomized trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients Bone Marrow Transplant 28 2001 484-490
43. Nicholson V.A. Whimbey E. Champlin R. et al. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis Bone Marrow Transplant 19 1997 37-41
44. Hebart H. Schroder A. Loffler J. et al. Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation J Infect Dis 175 1997 1490-1493
45. Hebart H. Wuchter P. Loeffler J. et al. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant Bone Marrow Transplant 28 2001 213-218
46. Hebart H. Rudolph T. Loeffler J. et al. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation Bone Marrow Transplant 30 2002 181-187
47. Boeckh M. Leisenring W. Riddell S.R. et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity Blood 101 2003 407-414
48. Li C.R. Greenberg P.D. Gilbert M.J. et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood 83 1994 1971-1979
49. Hakki M. Riddell S.R. Storek J. et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation Blood 102 2003 3060-3067